Allylamine-containing liposomes
    1.
    发明授权
    Allylamine-containing liposomes 失效
    含烯酰胺的脂质体

    公开(公告)号:US06623753B1

    公开(公告)日:2003-09-23

    申请号:US08881216

    申请日:1997-06-24

    IPC分类号: A61K9127

    CPC分类号: A61K31/135 A61K9/127

    摘要: The invention concerns liposomal preparations comprising as the active agent a compound of formula I in free base form or in acid addition salt form. It also concerns a method of preparation of such liposomal preparations by encapsulating a compound of formula I with an appropriate liposome forming material, a corresponding pharmaceutical compositions, and methods of treatment of systemic, topical and pulmonal fungal infections.

    摘要翻译: 本发明涉及包含作为活性剂的式I化合物游离碱形式或以酸加成盐形式的脂质体制剂。 它还涉及通过用合适的脂质体形成材料包封式I化合物,相应的药物组合物和治疗全身性,局部和肺部真菌感染的方法来制备这种脂质体制剂的方法。

    Composite Materials Loaded with Therapeutic and Diagnostic Agents Comprising Polymer Nanoparticles and Polymer Fibers
    6.
    发明申请
    Composite Materials Loaded with Therapeutic and Diagnostic Agents Comprising Polymer Nanoparticles and Polymer Fibers 审中-公开
    由聚合物纳米颗粒和聚合物纤维组成的包含治疗和诊断剂的复合材料

    公开(公告)号:US20120148493A1

    公开(公告)日:2012-06-14

    申请号:US13256872

    申请日:2010-03-16

    CPC分类号: A61K9/5153 A61K9/70

    摘要: The invention relates to composite materials comprising polymer nanofibers and polymer nanoparticles, wherein at least one of the two polymer materials is loaded with a substance selected from therapeutic and diagnostic agents. Fibers and nanoparticles can comprise identical or different polymers; the polymer materials are, however, biocompatible in every case. Therapeutic and diagnostic agents can be hydrophilic or lipophilic and the two polymer materials likewise. The at least one polymer material and the substance with which said material is loaded are either both hydrophilic or both lipophilic. The polymer nanoparticles of the composite materials have a diameter of 10 nm to 600 nm. The polymer fibers have diameters of 10 nm to 50 μm and lengths of 1 μm to several meters. The invention further relates to a method for producing said composite materials. Polymer nanoparticles can be produced in different ways, such as through controlled precipitation of a polymer solution that optionally comprises a loading substance. The nanoparticles are then mixed with another polymer and a loading substance as applicable, depending on whether particles, fibers or both are to be loaded with substance. The processing of this solution into composites comprising polymer fibers polymer nanoparticles can occur by means of electrospinning, melt spinning, extruding or template process. Composite materials according to the invention are suitable for the production of pharmaceuticals that release therapeutically or diagnostically effective substances slowly and in a controlled manner.

    摘要翻译: 本发明涉及包含聚合物纳米纤维和聚合物纳米颗粒的复合材料,其中两种聚合物材料中的至少一种负载有选自治疗剂和诊断剂的物质。 纤维和纳米颗粒可以包含相同或不同的聚合物; 然而,聚合物材料在每种情况下都是生物相容的。 治疗和诊断剂可以是亲水的或亲脂的,并且两种聚合物材料同样。 所述至少一种聚合物材料和所述材料被加载的物质既是亲水的,也是亲油的。 复合材料的聚合物纳米颗粒具有10nm至600nm的直径。 聚合物纤维的直径为10nm〜50μm,长度为1〜数米。 本发明还涉及一种生产所述复合材料的方法。 聚合物纳米颗粒可以以不同的方式制备,例如通过可选地包含负载物质的聚合物溶液的可控沉淀。 然后将纳米颗粒与另一种聚合物和负载物质混合,这取决于颗粒,纤维或两者是否被装载物质。 将该溶液加工成包含聚合物纤维聚合物纳米颗粒的复合材料可以通过静电纺丝,熔融纺丝,挤出或模板方法进行。 根据本发明的复合材料适用于缓慢地并以受控方式释放治疗或诊断有效物质的药物。

    Pharmaceutical compositions
    8.
    发明授权
    Pharmaceutical compositions 失效
    药物组合物

    公开(公告)号:US5593686A

    公开(公告)日:1997-01-14

    申请号:US314167

    申请日:1994-09-28

    IPC分类号: A61K9/70 A61K31/40 A61F13/02

    摘要: The present invention provides a pharmaceutical composition for the transdermal systemic administration of an active agent characterized in that the active agent is bopindolol or methysergide. Also the present invention provides a pharmaceutical composition for the transdermal systemic administration of a pharmacologically active agent characterized in that it contains bopindolol, tizanidine, clemastine, ketotifen or methysergide as active agent in a reservoir comprising a hydrophilic polymer. Furthermore a pharmaceutical composition for the transdermal systemic administration of pharmacologically active agents characterized in that the pharmacologically active agent is in a reservoir comprising a polyacrylate polymer containing cationic ester groups.

    摘要翻译: 本发明提供了一种用于经皮全身给药活性剂的药物组合物,其特征在于活性剂是苯吲哚洛尔或甲基麦角苷。 本发明还提供了一种药物组合物,其用于药理学活性剂的经皮系统性给药,其特征在于在包含亲水性聚合物的储库中含有苯妥萘洛,替扎尼定,克立马斯酮,酮替芬或甲基麦角苷作为活性剂。 此外,用于经皮系统施用药理活性剂的药物组合物,其特征在于药理活性剂在包含含有阳离子酯基的聚丙烯酸酯聚合物的储库中。

    PHARMACEUTICAL COMPOSITIONS
    9.
    发明申请
    PHARMACEUTICAL COMPOSITIONS 审中-公开
    药物组合物

    公开(公告)号:US20110305742A1

    公开(公告)日:2011-12-15

    申请号:US13090788

    申请日:2011-04-20

    IPC分类号: A61K9/00 A61P9/00

    摘要: A device implantable into a human or animal body comprising a biodegradable polymer which comprises ethylene carbonate units of the formula A -(—C(O)—O—CH2—CH2—O—)-  A having an ethylene carbonate content of 70 to 100 Mol %, an intrinsic viscosity of 0.4 to 4.0 dl/g measured in chloroform at 20° C. at a concentration of 1 g/dl and a glass transition temperature of from 5 to 50° C., degradable by surface erosion which is governed by a non-hydrolytic mechanism.

    摘要翻译: 一种可植入人或动物体内的装置,其包含可生物降解的聚合物,其包含具有70-100的碳酸亚乙酯含量的式A-(-C(O)-O-CH 2 -CH 2 -O - ) - 的亚碳酸酯单元 分子%,特性粘度为0.4〜4.0dl / g,在氯仿中在20℃下以1g / dl的浓度和5〜50℃的玻璃化转变温度测定,可通过表面侵蚀进行降解 通过非水解机理。